Global Biopharmaceutical CDMO Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Biopharmaceutical CDMO market size will reach 34,652 Million USD in 2025 and is projected to reach 83,306 Million USD by 2032, with a CAGR of 13.35% (2025-2032). Notably, the China Biopharmaceutical CDMO market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
A biopharmaceutical Contract Development and Manufacturing Organization (CDMO) is a company that provides contract services for the development, manufacturing, and testing of biopharmaceutical products on behalf of pharmaceutical and biotechnology companies. These CDMOs offer a comprehensive range of services, including process development, analytical testing, formulation development, cell line development, and manufacturing of biologics such as monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. By outsourcing these activities to a CDMO, companies can leverage the CDMO's expertise, facilities, and resources to accelerate product development, reduce costs, and focus on core competencies while ensuring quality, safety, and compliance with regulatory standards.
The major global suppliers of Biopharmaceutical CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Biopharmaceutical CDMO. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Biopharmaceutical CDMO market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Biopharmaceutical CDMO market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biopharmaceutical CDMO industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Biopharmaceutical CDMO Include:
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi AppTech
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Biopharmaceutical CDMO Product Segment Include:
Cell and Gene Therapies
Antibodies
Vaccines
Others
Biopharmaceutical CDMO Product Application Include:
SMBs
Large Companies
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Biopharmaceutical CDMO Industry PESTEL Analysis
Chapter 3: Global Biopharmaceutical CDMO Industry Porter's Five Forces Analysis
Chapter 4: Global Biopharmaceutical CDMO Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Biopharmaceutical CDMO Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Biopharmaceutical CDMO Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Biopharmaceutical CDMO Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Biopharmaceutical CDMO market size will reach 34,652 Million USD in 2025 and is projected to reach 83,306 Million USD by 2032, with a CAGR of 13.35% (2025-2032). Notably, the China Biopharmaceutical CDMO market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
A biopharmaceutical Contract Development and Manufacturing Organization (CDMO) is a company that provides contract services for the development, manufacturing, and testing of biopharmaceutical products on behalf of pharmaceutical and biotechnology companies. These CDMOs offer a comprehensive range of services, including process development, analytical testing, formulation development, cell line development, and manufacturing of biologics such as monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. By outsourcing these activities to a CDMO, companies can leverage the CDMO's expertise, facilities, and resources to accelerate product development, reduce costs, and focus on core competencies while ensuring quality, safety, and compliance with regulatory standards.
The major global suppliers of Biopharmaceutical CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Biopharmaceutical CDMO. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Biopharmaceutical CDMO market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Biopharmaceutical CDMO market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biopharmaceutical CDMO industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Biopharmaceutical CDMO Include:
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi AppTech
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Biopharmaceutical CDMO Product Segment Include:
Cell and Gene Therapies
Antibodies
Vaccines
Others
Biopharmaceutical CDMO Product Application Include:
SMBs
Large Companies
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Biopharmaceutical CDMO Industry PESTEL Analysis
Chapter 3: Global Biopharmaceutical CDMO Industry Porter's Five Forces Analysis
Chapter 4: Global Biopharmaceutical CDMO Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Biopharmaceutical CDMO Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Biopharmaceutical CDMO Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Biopharmaceutical CDMO Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Biopharmaceutical CDMO Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Biopharmaceutical CDMO Product by Type
- 1.2.1 Cell and Gene Therapies
- 1.2.2 Antibodies
- 1.2.3 Vaccines
- 1.2.4 Others
- 1.3 Biopharmaceutical CDMO Product by Application
- 1.3.1 SMBs
- 1.3.2 Large Companies
- 1.4 Global Biopharmaceutical CDMO Market Size Analysis (2020-2032)
- 1.5 Biopharmaceutical CDMO Market Development Status and Trends
- 1.5.1 Biopharmaceutical CDMO Industry Development Status Analysis
- 1.5.2 Biopharmaceutical CDMO Industry Development Trends Analysis
- 2 Biopharmaceutical CDMO Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Biopharmaceutical CDMO Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Biopharmaceutical CDMO Market Analysis by Country
- 4.1 Global Biopharmaceutical CDMO Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Biopharmaceutical CDMO Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Biopharmaceutical CDMO Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.5 China Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.6 France Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.14 India Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Biopharmaceutical CDMO Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Biopharmaceutical CDMO Market Revenue by Key Suppliers (2021-2025)
- 5.2 Biopharmaceutical CDMO Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Biopharmaceutical CDMO Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Biopharmaceutical CDMO Market Analysis by Type
- 6.1 Global Biopharmaceutical CDMO Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Biopharmaceutical CDMO Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Lonza
- 7.1.1 Lonza Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Lonza Biopharmaceutical CDMO Product Portfolio
- 7.1.3 Lonza Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Catalent
- 7.2.1 Catalent Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Catalent Biopharmaceutical CDMO Product Portfolio
- 7.2.3 Catalent Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Samsung Biologics
- 7.3.1 Samsung Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Samsung Biologics Biopharmaceutical CDMO Product Portfolio
- 7.3.3 Samsung Biologics Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 FUJIFILM Diosynth Biotechnologies
- 7.4.1 FUJIFILM Diosynth Biotechnologies Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Product Portfolio
- 7.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Boehringer Ingelheim
- 7.5.1 Boehringer Ingelheim Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Boehringer Ingelheim Biopharmaceutical CDMO Product Portfolio
- 7.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 WuXi AppTech
- 7.6.1 WuXi AppTech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 WuXi AppTech Biopharmaceutical CDMO Product Portfolio
- 7.6.3 WuXi AppTech Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Recipharm
- 7.7.1 Recipharm Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Recipharm Biopharmaceutical CDMO Product Portfolio
- 7.7.3 Recipharm Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Thermo Fisher Scientific
- 7.8.1 Thermo Fisher Scientific Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Thermo Fisher Scientific Biopharmaceutical CDMO Product Portfolio
- 7.8.3 Thermo Fisher Scientific Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 AGC Biologics
- 7.9.1 AGC Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 AGC Biologics Biopharmaceutical CDMO Product Portfolio
- 7.9.3 AGC Biologics Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Rentschler Biopharma
- 7.10.1 Rentschler Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Rentschler Biopharma Biopharmaceutical CDMO Product Portfolio
- 7.10.3 Rentschler Biopharma Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 KBI Biopharma
- 7.11.1 KBI Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 KBI Biopharma Biopharmaceutical CDMO Product Portfolio
- 7.11.3 KBI Biopharma Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 Siegfried
- 7.12.1 Siegfried Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Siegfried Biopharmaceutical CDMO Product Portfolio
- 7.12.3 Siegfried Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 Aenova Group
- 7.13.1 Aenova Group Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 Aenova Group Biopharmaceutical CDMO Product Portfolio
- 7.13.3 Aenova Group Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 GenScript
- 7.14.1 GenScript Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 GenScript Biopharmaceutical CDMO Product Portfolio
- 7.14.3 GenScript Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.15 ProBioGen
- 7.15.1 ProBioGen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.15.2 ProBioGen Biopharmaceutical CDMO Product Portfolio
- 7.15.3 ProBioGen Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.16 Northway Biotech
- 7.16.1 Northway Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.16.2 Northway Biotech Biopharmaceutical CDMO Product Portfolio
- 7.16.3 Northway Biotech Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.17 3P Biopharmaceuticals
- 7.17.1 3P Biopharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.17.2 3P Biopharmaceuticals Biopharmaceutical CDMO Product Portfolio
- 7.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Biopharmaceutical CDMO Industry Chain Analysis
- 8.2 Biopharmaceutical CDMO Product Downstream Application Analysis
- 8.2.1 Global Biopharmaceutical CDMO Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Biopharmaceutical CDMO Revenue and Forecast by Application (2020-2032)
- 8.3 Biopharmaceutical CDMO Typical Downstream Customers
- 8.4 Biopharmaceutical CDMO Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
